Open AccessP949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3
Author(s) -
Lesokhin A. M.,
Arnulf B.,
Niesvizky R.,
Mohty M.,
Bahlis N. J.,
Tomasson M. H.,
RodrίguezOtero P.,
Quach H.,
Raje N. S.,
Iida S.,
Raab M.S.,
Czibere A.,
Sullivan S.,
Leip E.,
Viqueira A.,
Leleu X.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846664.78859.dd
Subject(s) - medicine , cytokine release syndrome , adverse effect , multiple myeloma , regimen , gastroenterology , refractory (planetary science) , oncology , cancer , chimeric antigen receptor , immunotherapy , physics , astrobiology